The global microbiome sequencing services market was valued at approximately USD 2,610.6 Million in 2024 and is expected to surge - reaching nearly USD 11,260.5 Million by 2033, growing at a robust CAGR of 16.75% during 2025-2033. This strong ascent is fueled by innovation in sequencing technologies, expanding microbiome-based therapeutics (e.g., FMT), and broader adoption across healthcare, agriculture, and environmental sectors.
STUDY ASSUMPTION YEARS
- BASE YEAR: 2024
- HISTORICAL YEAR: 2019–2024
- FORECAST YEAR: 2025–2033
MICROBIOME SEQUENCING SERVICES MARKET KEY TAKEAWAYS
- Market size (2024): USD 2,610.6 Million; projected to reach USD 11,260.5 Million by 2033 - a 16.75% CAGR.
- Technology leadership: Sequencing by Synthesis (SBS) dominates due to its precision and scalability.
- Research trend: Outsourced studies outpace internal research, enabling access to specialized expertise.
- Lab adoption: Wet labs hold prominence because they handle critical sample processing before sequencing.
- Application focus: Shotgun metagenomic sequencing leads, providing comprehensive microbial profiling.
- End users: Pharmaceutical and biotech companies are primary purchasers, harnessing microbiome insights for drug and therapy development.
MARKET GROWTH FACTORS
1. Cutting-Edge Sequencing Technologies & Scalability
Advancements like SBS and shotgun metagenomics are enhancing accuracy, throughput, and cost-efficiency. SBS remains dominant for analyzing complex microbial populations, while shotgun techniques capture whole-genome data at diminishing costs. These improvements have lowered testing expenses, broadened accessibility, and amplified applications - from clinical diagnostics to agricultural soil profiling - making microbiome sequencing an indispensable research tool.
2. Expanding Adoption in Therapeutics, Agriculture & Environmental Science
Growing awareness of the microbiome’s role in health and the environment is accelerating demand. Clinical fields are integrating microbiome analysis into diagnostics and FMT strategies. Simultaneously, sectors like precision agriculture and environmental microbiome monitoring are leveraging sequencing data to improve crop yields, soil health, and ecosystem assessment. This cross-industry uptake is a powerful catalyst for market expansion.
3. Outsourced Services & Lab Infrastructure
With outsourced research dominating, organizations tap into specialized labs to manage sequencing workflows, data processing, and bioinformatics. Wet labs - trusted for their rigorous sample prep - are particularly essential. This model reduces in-house R&D burdens and accelerates project timelines. As demand grows, the microbiome services ecosystem continues strengthening, with more service providers and capacity dedicated to outsourced pipelines.
Request for a sample copy of this report:
https://www.imarcgroup.com/microbiome-sequencing-services-market/requestsample
MARKET SEGMENTATION
Breakup by Technology
- Sequencing by Synthesis (SBS)
- Sequencing by Ligation (SBL)
- Pyrosequencing
- Sanger Sequencing
- Others
Breakup by Research Type
- Outsourced Research
- Internal Research
Breakup by Laboratory Type
- Dry Labs
- Wet Labs
Breakup by Application
- Shotgun Sequencing
- Targeted Gene Sequencing
- RNA Sequencing
- Whole Genome Sequencing
- Others
Breakup by End User
- Pharmaceutical and Biotechnology Companies
- Research and Academic Institutes
- Others
Breakup by Region
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
REGIONAL INSIGHTS
North America dominates, driven by integration of microbiome sequencing into clinical diagnostics, therapeutics, and precision medicine. Strong R&D infrastructure, abundant clinical trials targeting conditions like IBD, cancer, and metabolic disorders, and regulatory support make the region a prime growth engine.
RECENT DEVELOPMENTS & NEWS
Recent innovations include long‑read sequencing services launched by Microbiome Insights Inc. for 16S rRNA and metagenomic analyses, enhancing depth and accuracy. Concurrently, BIOHM Health Inc. partnered with Virginia Tech to integrate AI into microbiome-based wellness solutions, signaling growing focus on smart diagnostics and personalized health interventions.
KEY PLAYERS
BaseClear B.V., Clinical-Microbiomics A/S, Diversigen Inc (OraSure Technologies Inc.), Mérieux NutriSciences, Metabiomics Corporation (BioSpherex LLC), Microbiome Insights Inc., Microbiome Therapeutics LLC, Molecular Research LP, Molzym GmbH & Co. KG, Resphera Biosciences LLC, Shanghai Realbio Technology (RBT) Co. Ltd., Zymo Research Corporation, etc.
Ask Analyst for Customization:
https://www.imarcgroup.com/request?type=report&id=4357&flag=C
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include a thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape, and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
